Day One’s phase II findings with ‘drug to beat’ may inaugurate new era in pediatric brain cancer June 13, 2022 By Randy Osborne Day One Biopharmaceuticals Inc.’s phase II data with tovorafenib from the Firefly-1 study in pediatric brain cancer dazzled Wall Street, and shares (NASDAQ:DAWN) closed $14.96, up $8.34, or 126%.Read More
